Brief: Suven Life Sciences says secures two product patents in Europe and Israel
18/10/2016 05:32
Oct 18 (Reuters) - Suven Life Sciences Ltd SUVP.NS
* Secures two product patents in europe and israel
* Patents corresponding to the new chemical entities for the
treatment of disorders associated with neurodegenerative
diseases
* Patents are valid through 2030 and 2029
Source text: http://bit.ly/2dnOtFo
Further company coverage: SUVP.NS
(Bengaluru newsroom)
((ReutersIndia.snapping@thomsonreuters.com ;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Patient Enrollment In Global Phase-3 Masupirdine Study
India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment
Brief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant